

11/03/2022

METAPHARMACEUTICAL



F&A PHARMA-Handels-GmbH
Senhoeferring 41 • D-46285 Derten • Germany
Phone: +49 (0) 2369-9261947 • Fax: +49 (0) 2369-3261950



Works :
294, G.I.D.C., Estate,
Ankleshwar - 393 002.
Gujarat, India.

N DE LOTE:

0430322

Phone : +91-2646-251519/ 252626
Fax : +91-2646-250051
Website : www.cadilapharma.com

Page 1 of 2

Name of Finished Drug substance: Fluoxetine Hydrochloride Ph.Eur/BP+IH.

Manufactured By.	Cadila Pharmaceuticals Limited, Ankleshwar		
Batch No.	22FH005	A.R. No.	22FP0047
Manufacturing Date	JANUARY 2022	Qty. Mfgd.	150.25 Kg.
Expiry Date	DECEMBER 2026	Sample Qty.	125.62 gm
Specification No	FPS/239	CEP No	R1-CEP 2004-207-Rev 05
Storage condition	Store in a tightly closed container at room temperature. (Not more than 25°C, excursion allowed 15°C to 30°C).		
Certificate of Analysis			
Test	Requirements	Results	
Characters: A. Description B. Solubility	A. White or almost white crystalline powder. B. Sparingly soluble in water and in methylene chloride, Freely soluble in methanol.	White crystalline powder. Sparingly soluble in water and in methylene chloride, Freely soluble in methanol.	
Identification A. By IR	A. The infrared absorption spectrum obtained from the sample should be concordant with the spectrum obtained from Fluoxetine Hydrochloride for ID and assay CRS/ Fluoxetine Hydrochloride working standard. B. Should be responds the chlorides	The infrared absorption spectrum obtained from the sample is concordant with the spectrum obtained from Fluoxetine Hydrochloride working standard.	
B. Test for chloride		Complies	
Appearance of solution	Solution should be clear and colorless	Solution clear and colorless	
pH	Between 4.5 and 6.5	6.28	
Optical rotation	Between - 0.05° and + 0.05°	-0.00°	
Water content (By KF)	Not more than 0.50 % w/w	0.06 % w/w	
Sulfated ash	Not more than 0.10 % w/w	0.05 % w/w	
Related substances (By HPLC) Impurity A Impurity B Dimethyl amine impurity Unspecified impurity Total impurities	Not more than 0.15 % Not more than 0.10 % Not more than 0.10 % Not more than 0.10 % Not more than 0.30 %	Below Detection limit Below Detection limit Below Quantification limit 0.01 % 0.02 %	
Assay (By HPLC)	Not less than 98.0 % w/w and not more than 102.0 % w/w of C ₁₇ H ₁₈ F ₃ NO.HCl, calculated on the anhydrous basis	99.3 % w/w	
Residual solvents (By GC) Benzene Ethyl acetate Toluene	Not more than 1 ppm Not more than 5000 ppm Not more than 100 ppm	Not Detected Not Detected Not Detected	
Additional Test:			
Particle size (By Malvern analyzer)	90 % less than 50 μ	90 % particles 24.8 μ	



Remarks: The material complies with respect to the above specifications.

Statement of Compliance: We, hereby confirm that this batch is manufactured in accordance with current Good Manufacturing Practices.

	Prepared By	Checked By	Approved By
Name	Ankit Pokar	Kaushik Kahar	Hasmukh Vamja
Designation	Sr. Officer-QA	Dy. Manager-QA	Sr. Manager-QA
Signature			
Date	19.02.22	19.02.22	19.02.22

F/QA007/14/13.04.18

Registered Office :
"Cadila Corporate Campus,"
Sarkhej-Dholka Road, Bhat,
Ahmedabad - 382 210, Gujarat, India.

Phone : +91-2718-225001-15
Fax : +91-2718-225039
Website : www.cadilapharma.com
CIN : U24231GJ1991PLC015132

The Care Continues...

